National
Portugal: Infarmed withdraws two cosmetics with CBD from the market
The Infarmed – National Authority for Medicines and Health Products IP today ordered the withdrawal from the market of Cannabiron CBD and Good Cannabis creams, as they contain CBD (cannabidiol), whose use is “prohibited in cosmetic products”. The document warns that cosmetics that include CBD in their composition “cannot be marketed”, entities that have these products “should not make them available” and consumers “should not use them”.
In February 2022, Infarmed had already disclosed the informative circular nº 014/CD/100.20.200, where it established that “the substance cannabidiol (CBD), as it is obtained through extracts or tinctures of cannabis or its resin, is not allowed in the composition of cosmetic products”. At the time, Infarmed also reinforced that the use of CBD extracted from “cannabis for industrial purposes” (or hemp) was also prohibited. In a footnote, the document signed by the president of Infarmed, Rui Santos Ivo, made it clear that “cosmetic products cannot therefore contain the following substances/preparations related to the cannabis plant, regardless of their tetrahydrocannabinol (THC) content” – “which includes (sic) industrial hemp varieties”.
According to the authority, the informative circular No. 083/CD/100.20.200 released today follows a complaint and the respective assessment by Infarmed, which “verified the existence in the national market of Cannabiron CBD cream products, whose “Responsible Person” is the company Dietmed, Lda., and Good Cannabis cream, whose “Responsible Person” Responsible” is the company Vitaceutics, Lda.”
These products “have in their composition the substance cannabidiol which, as it is obtained through extracts or tinctures of cannabis or its resin, is not allowed in the composition of cosmetic products”.
Thus, Infarmed determines the following:
- Cosmetic products that include the substance cannabidiol in their composition cannot be marketed.
- Entities that have these products must not make them available.
- Consumers who have these products should not use them.
For any additional information regarding the Cannabiron CBD cream and Good Cannabis cream products, contact the respective “Responsible Persons”, ie the companies Dietmed, Lda. and Vitaceutics, Lda.
For any additional information, Infarmed provides the following contacts:
Information Center for Medicines and Health Products (CIMI)
Phone: +351 21 798 7373; E-mail: cimi@infarmed.pt; Medication Line: 800 222 444
____________________________________________________________________________________________________
[Disclaimer: Please note that this text was originally written in Portuguese and is translated into English and other languages using an automatic translator. Some words may differ from the original and typos or errors may occur in other languages.]____________________________________________________________________________________________________
What do you do with €3 a month? Become one of our Patrons! If you believe that independent cannabis journalism is necessary, subscribe to one of the levels of our Patreon account and you will have access to unique gifts and exclusive content. If there are many of us, we can make a difference with little!
With a degree in Journalism from the University of Coimbra, Laura Ramos has a postgraduate degree in Photography and has been a Journalist since 1998. Winner of the Business of Cannabis Awards in the category "Journalist of the Year 2024", Laura was a correspondent for Jornal de Notícias in Rome, Italy, and Press Officer in the Office of the Minister of Education of the 21st Portuguese Government. She has an international certification in Permaculture (PDC) and created the street-art photography archive “Say What? Lisbon” @saywhatlisbon. Co-founder and Editor of CannaReporter® and coordinator of PTMC - Portugal Medical Cannabis, Laura directed the documentary “Pacientes” and was part of the steering group of the first Postgraduate Course in GxP's for Medicinal Cannabis in Portugal, in partnership with the Military Laboratory and the Faculty of Pharmacy of the University of Lisbon.



